Regenesis Biomedical focuses on non-drug pain management solutions, primarily through their flagship product, Reprieve. This technology utilizes electromagnetic shortwave diathermy therapy, allowing patients to self-treat at home. The company emphasizes its commitment to improving patient health and quality of life, with over 24,000 veterans having been treated using their devices. The Reprieve system is designed to be environmentally conscious, eliminating the need for disposables, and is supported by dedicated patient care coordinators who assist with treatment. Clinical outcomes have shown a reduction in pain and a decreased reliance on pain medications, making it a viable option for those seeking alternative pain relief methods.

In addition to the Reprieve device, Regenesis offers the Reprieve 60 Duo, which includes two treatment pads, and a single pad option known as Reprieve by Regenesis CW. The Compliance and Compatibility Assessment (CCA) device is also part of their offerings, which evaluates whether a patient would benefit from long-term use of the purchased device over a 60-day period. This comprehensive approach ensures that patients receive tailored support and effective treatment options, reinforcing Regenesis Biomedical's mission to enhance the lives of individuals dealing with pain.

United States

Regenesis Biomedical is a medical device firm that develops and commercializes non-drug pain relief equipments for the treatment of chronic diseases.

Regenesis Biomedical

Company Details